about
MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets.Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordomaIncidence and survival patterns of cranial chordoma in the United States.Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma.Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell linesGenotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1FAS/FASL are dysregulated in chordoma and their loss-of-function impairs zebrafish notochord formation.Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma.Overexpression of adenosine deaminase acting on RNA 1 in chordoma tissues is associated with chordoma pathogenesis by reducing miR‑125a and miR‑10a expressionExperimental study on differences in clivus chordoma bone invasion: an iTRAQ-based quantitative proteomic analysisReduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients.Multidisciplinary approach of lumbo-sacral chordoma: From oncological treatment to reconstructive surgery.Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFRExpression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.Clinicopathologic implications of CD8(+)/Foxp3(+) ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients.
P2860
Q30414321-2BC129BA-D197-4F6B-AF35-A67E1EE2AE6AQ33274821-55830880-53C8-4266-B20F-AB2EE0E63D98Q33274950-1C073A89-CBFB-4E7A-BC61-BFE45C43F8ECQ33274967-BC0A0E26-640E-4C18-8260-97117B11566FQ33275146-F91F4291-A482-494E-A8C1-5CE1202F9788Q33275282-6458FD35-F80B-4E33-83F6-EC9BE89B5705Q33275318-1377F2FB-4DAF-4C8C-80AB-9D3FF2C31496Q33275346-FAE273CB-5955-4C79-89E8-1444D2932B06Q33275385-0502B57A-2D2C-44E8-B254-8C3DE26DCEB5Q33275542-2DA7BC53-E24B-4BE2-BFA8-092D2A39B7C4Q33275585-726E9962-41A0-4C81-B5D4-F91CE57834D7Q33275607-5F62A991-77A8-4E10-A923-700084AAEC0CQ33275786-942D96AD-D772-48A9-9E90-09A80BCA15D9Q33276057-18C45D9F-7538-48D6-8DAD-22708489AB77Q33276164-E608D573-34FF-4416-B8F6-0718C0050FE8Q47756173-FEC4D485-1D95-4168-B65E-EAED28BF2508
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Novel therapeutic targets in chordoma.
@ast
Novel therapeutic targets in chordoma.
@en
type
label
Novel therapeutic targets in chordoma.
@ast
Novel therapeutic targets in chordoma.
@en
prefLabel
Novel therapeutic targets in chordoma.
@ast
Novel therapeutic targets in chordoma.
@en
P2093
P2860
P1476
Novel therapeutic targets in chordoma.
@en
P2093
Daniel Sciubba
Kyriakos Papadimitriou
Mohamad Bydon
Timothy Witham
Ziya Gokaslan
P2860
P304
P356
10.1517/14728222.2012.714772
P407
P577
2012-08-04T00:00:00Z